In this line, Juul et al. (2024) designed oxaliplatin-loaded, HER2-targeted, MMP-sensitive L and evaluated the interaction between L and cancer cells by inserting a protease-sensitive cleavable peptide linker into the base of each PEG. Here, ERBB2 is linked to cancer.